ERBB2 and breast carcinoma: After receiving an endocrine therapy, PIK3CA mutated HR+/HER2-breast cancer patients treated with alpelisib plus fulvestrant showed a median progression-free survival (PFS) of 11 months vs. 5.7 months for patients treated with placebo plus fulvestrant (HR = 0.65, 95% CI: 0.50, 0.85, one-sided p-value = 0.00065) [13].